The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 63,128 | 1,672,714 | SH | SOLE | 1,672,714 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 59,519 | 3,967,900 | SH | SOLE | 3,967,900 | 0 | 0 | ||
| Alder Biopharmaceuticals Inc. | COM | 014339105 | 26,305 | 802,724 | SH | SOLE | 802,724 | 0 | 0 | ||
| BioDelivery Sciences International, Inc. | COM | 09060J106 | 608 | 225,281 | SH | SOLE | 225,281 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 15,184 | 1,543,118 | SH | SOLE | 1,543,118 | 0 | 0 | ||
| NanoString Technologies, Inc. | COM | 63009R109 | 15,042 | 752,857 | SH | SOLE | 752,857 | 0 | 0 | ||
| Nexvet Biopharma public limited company | ORD SHS | G6503X109 | 3,736 | 900,155 | SH | SOLE | 900,155 | 0 | 0 | ||
| Orexigen Therapeutics, Inc. | COM | 686164104 | 1,802 | 542,755 | SH | SOLE | 542,755 | 0 | 0 | ||
| Universal American Corp. | COM | 91338E101 | 21,579 | 2,820,791 | SH | SOLE | 2,820,791 | 0 | 0 | ||
| Zafgen, Inc. | COM | 98885E103 | 2,516 | 760,046 | SH | SOLE | 760,046 | 0 | 0 | ||